Valuation: Agenus Inc.

Market Cap 38Cr 33Cr 31Cr 28Cr 54Cr 3.62TCr 54Cr 377.71Cr 146.36Cr 1.85TCr 141.31Cr 138.24Cr 5.94TCr P/E 2026 *
33.9x
P/E 2027 * -17.7x
Enterprise Value 38Cr 33Cr 31Cr 28Cr 54Cr 3.62TCr 54Cr 377.71Cr 146.36Cr 1.85TCr 141.31Cr 138.24Cr 5.94TCr EV / Sales 2026 *
3.01x
EV / Sales 2027 * 3.25x
Free-Float
93.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week-2.11%
Current month-15.81%
1 month+1.46%
3 months+139.54%
6 months+151.05%
Current year+166.24%
1 week 8.08
Extreme 8.08
10.31
1 month 6.66
Extreme 6.66
10.31
Current year 2.71
Extreme 2.71
10.31
1 year 2.71
Extreme 2.71
10.31
3 years 1.38
Extreme 1.38
23.2
5 years 1.38
Extreme 1.38
117.2
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 73 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Chief Executive Officer

19,71,500 4.4054%
05/08/26 Free

Director

50,000 0.1117%
05/08/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%-2.11%+101.93%-59.42% 38Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+20.19%+81.44% 5.74TCr
+0.89%-0.63%+2.17%+36.19% 4.76TCr
+0.36%+0.81%+342.39%+742.40% 4.43TCr
-0.96%-4.50%+24.96%+35.38% 4.25TCr
-0.20%-0.77%+4.13%+105.50% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.33%+22.72% 2.85TCr
+0.05%-1.64%-8.14%-11.37% 2.43TCr
Average -0.17%-0.74%+57.56%+109.74% 3.91TCr
Weighted average by Cap. +0.12%-0.84%+57.00%+138.07%

Financials

2026 *2027 *
Net sales 13Cr 11Cr 10Cr 9.46Cr 18Cr 1.2TCr 18Cr 125.65Cr 49Cr 615.29Cr 47Cr 46Cr 1.97TCr 12Cr 10Cr 9.62Cr 8.77Cr 17Cr 1.11TCr 17Cr 116.38Cr 45Cr 569.91Cr 44Cr 43Cr 1.83TCr
Net income 3.94Cr 3.5Cr 3.27Cr 2.98Cr 5.62Cr 378.76Cr 5.67Cr 40Cr 15Cr 193.63Cr 15Cr 14Cr 621.42Cr -2.86Cr -2.54Cr -2.37Cr -2.16Cr -4.07Cr -274.46Cr -4.11Cr -29Cr -11Cr -140.31Cr -11Cr -10Cr -450.3Cr
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
02/26/02 $8.360 +0.36% 10,85,594
01/26/01 $8.330 -16.11% 19,51,997
30/26/30 $9.930 +0.40% 13,67,323
29/26/29 $9.890 +4.88% 15,01,456
28/26/28 $9.430 +10.42% 27,66,014
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.360USD
Average target price
26.33USD
Spread / Average Target
+214.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock